Angio-oedema in a patient treated with etanercept for rheumatoid arthritis

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 6, 2009, Pages 488-490

  Sendur, Omer Faruk ^a   Turan, Yasemin ^a,b   Berkit, Isil Karatas ^a   Tastaban, Engin ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ANAMNESIS; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; EDEMA; FACE ERYTHEMA; FEMALE; HAND EDEMA; HUMAN; LIP DISEASE; LIP EDEMA; PERIORBITAL EDEMA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANGIOEDEMA; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 65549138855     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00401.x     Document Type: Article

References (21)

1. Harris ED. Rheumatoid arthritis. In : Kelley WN, Haris ED, Rudy S, Sledge CB (eds). Kelley's Textbook of Rheumatology, 4th edn. Elsevier Science, Philadelphia, PA, 1993 833 73.
2. Fleischman R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents; focus on the benefits and risks of etanercept. Drug Saf 2002 25 : 173 97. (Pubitemid 34492938)
3. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006 65 : 35 9. (Pubitemid 41815636)
4. Pierer M, Baerwald C. Biological therapy for the treatment of rheumatic diseases. Internist (Berl) 2008 49 : 938 46.
5. Kang MJ, Lee YH, Lee JJ. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Korean Med Sci 2006 21 : 946 9.
6. Li P, Schwarz EM. The TNF-α transgenic mouse model of inflammatory arthritis. Spriger Semin Immunopathol 2003 25 : 19 33. (Pubitemid 37000036)
7. Yamamura M. Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis efficacy evaluation, adverse effect detection, and prediction of clinical response. Nippon Rinsho 2007 65 : 1269 75.
8. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Ezp Rhermatol 2007 25 : 40 6. (Pubitemid 46477484)
9. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infection and Immunity 2001 69 : 1847 55. (Pubitemid 32187645)
10. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003 28 : 604 7. (Pubitemid 37430879)
11. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 86 : 242 51. (Pubitemid 47067483)
12. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006 33 : 2398 408. (Pubitemid 46067817)
13. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003 30 : 401 3. (Pubitemid 36152611)
14. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006 20 : 757 90. (Pubitemid 44350122)
15. Sànchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, Ruiz-Villaverde R. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol 2006 24 (5 Suppl 42 128.
16. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007 26 : 787 8. (Pubitemid 46554095)
17. Freeman AM, Dasgupta B. Angio-neurotic oedema associated with methotrexate treatment in rheumatoid arthritis. Rheumatology (Oxford) 1999 38 : 908. (Pubitemid 29507380)
18. Compalati E, Guerra L, Rogkakou A, Zanella C, Scordamaglia A, Passalacqua G. Angioedema after administration of methylprednisolone to treat drug allergy. Allergy 2007 62 : 1346 8. (Pubitemid 47537510)
19. Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995 74 : 155 9.
20. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005 53 : 373 88. (Pubitemid 41195957)
21. Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 2008 144 : 1190 4.